A new perspective focused on scalable cell therapy manufacturing argues that developers should shift from research workflows to GMP-ready systems earlier in development. The article emphasizes moving toward closed, automated processes and chemically defined media to reduce downstream regulatory friction. It also notes that early process design choices can help therapy sponsors bypass expensive comparability studies typically triggered by late-stage manufacturing changes. The framing is directed at easing scale-up and improving consistency as programs transition from early studies to regulated commercial production. For sponsors, the core operational message is that manufacturing scalability is not just a CMC milestone—it is a gating factor for clinical continuity and regulatory execution.